sign free newsletters sign free newsletters new drug zulresso work days not weeks takes current treatments food drug administration tuesday approved brexanolone drug specifically targeted treat postpartum depression common complication childbirth condition goes untreated new mothers fear stigmatized report symptoms brexanolone drug developed approved sage therapeutics cambridge mass.-based biotech company market new medicine brand zulresso approval important postpartum depression patients important company rare career introduce new medicine different said sage ceo jeff jonas approximately 400,000 women experience postpartum depression year u.s. according centers disease control prevention specialists half women postpartum depression diagnosed treated hailed zulresso arrival works fast spark awareness